This article offers general information about investing and the stock market, but should not be construed as personal investment advice. It has been provided without consideration of your personal circumstances or objectives. It should not be interpreted as an inducement, invitation or recommendation relating to any of the products listed or referred to. The value of investments can fall as well as rise, and you may get back less than you invested. Past performance is no guarantee of future results. If you’re not sure which investments are right for you, please get financial advice. The author holds no positions in any share mentioned.
Coronavirus vaccine stocks to watch
Here are the key companies involved in the COVID-19 vaccine race, their share prices and how to invest in them.
According to the World Health Organization (WHO), there are 48 candidate vaccines in clinical evaluation and the race is on to find a successful one – or several. Usually vaccines take years to create and test, but with the urgency to create this one, many countries are allowing phases to be conducted simultaneously.
As any company knows, successful results will mean a rise in its stock price. We’ve compiled some of the companies currently in the race to create a vaccine and what phase they’re currently in.
The different phases of vaccine creation
- Phase one. This includes testing the candidate on a small group to find out if there are any adverse reactions to it.
- Phase two. This phase tests whether the vaccine is safe for humans. The potential vaccine is tested on a larger group.
- Phase three. In this phase, the candidates are tested on a much larger scale with tens of thousands of people.
- Regulation. If all three phases are successful then it gets put to regulators. The regulation processes tend to differ between countries and have been slightly different due to the severity of COVID-19.
Who’s winning the coronavirus vaccine race?
There are a few companies currently in the lead, such as Pfizer and BioNTech, Moderna and University of Oxford and AstraZeneca. All of these companies have stated that their vaccines are more than 50% effective.
Check out the coronavirus vaccine race below.
What does a vaccine mean for investors?
Companies currently in phase 3
Johnson & Johnson – Ad26.COV2.S
Johnson & Johnson announced in September that it has launched its phase three trials for its COVID-19 vaccine. The phase one trial started in the US and Belgium in mid-July. It plans to have its first batches available for use in early 2021 and aims to provide more than 1 billion doses of its vaccine each year.
Novavax – NVX-CoV2373
Novavax‘s candidate started human trials in July which suggested that it is safe and effective. In September, it announced that it has initiated a phase three study for the potential vaccine.
Novavax has already been awarded a contract from the US Department of Defense to manufacture the vaccine.
University of Oxford/ AstraZeneca – ChAdOx1 nCoV-19
This candidate hasn’t reported any adverse reactions on humans so far. It says the volunteers have responded in the same way as animals that have been protected from the virus. It is currently being trialled on tens of thousands of volunteers
AstraZeneca will be responsible for manufacturing and distributing the vaccine.
Over 2 billion doses have been ordered by the UK, US, Europe and India.
Sinovac – CoronaVac
Started work in January. Phase 1 and 2 trials were made on 743 people and no adverse side effects have been reported.
It’s started on phase three, but phase two is not expected to be finished until the end of 2020.
Phase three will test the vaccine on almost 9,000 healthcare professionals in Brazil.
Primary results from phase three should be ready in September 2021, while the study is due to be finished by October 2021.
The China National Pharmaceutical Group has been working on a vaccine developed by the Beijing Institute of Biological Products and the Wuhan Institute of Biological Products.
Chairman Liu Jingzhen has reportedly already injected himself with the vaccine before clinical trials began.
It’s started working on phase three with thousands of volunteers in the UAE.
It’s been suggested by the chairman that Sinopharm will be ready before the end of the year.
Moderna – mRNA-1273
Moderna is working with the National Institute of Allergy and Infectious Diseases (NIAID). It was one of the first to get started on the vaccine. Phase two is currently in motion and has had positive results so far.
Phase 3 hasn’t yet started but has been approved to include 30,000 volunteers. It is estimated to be completed in October 2022 and the company plans to deliver 500 million doses per year.
BioNTech, Fosun Pharma and Pfizer
Some good news broke in November about BioNtech, Pfizer and Fosun Pharma’s vaccine which could be ready before the end of 2020. Two of its candidates have been through preliminary trials, one of which went on to do phase 2 and 3 trials on up to 30,000 volunteers. Pfizer and BioNTech plan to supply up to 100 million doses before the end of 2020 if they get regulatory approval.
The companies already have deals signed with numerous countries including the US, Canada, Japan and the UK.
Companies currently in phase 2
Cadila Healthcare (Zydus Cadila) – ZyCov-D
The potential vaccine has so far been found to be safe, and the company is due to start phase three in December 2020. This candidate is a 3-dose vaccine and the company plans to begin with the manufacturing of 100 million doses.
CanSino Biologics – Ad5-nCOV
CanSino Biologics has finished its phase 2 trials on more than 500 people in Wuhan, China. It is looking to test the potential candidate on more than 400,000 people in phase 3.
Anhui Zhifei Longcom Biopharmaceutical
Anhui Zhifei Longcom is working with the Chinese Academy of Sciences to create a vaccine. It started on phase 1 trials in May and started on phase 2 on 900 volunteers in July.
Companies in phase 1
The Institute of Medical Biology of the Chinese Academy of Medical Science
The Institute of Medical Biology of the Chinese Academy of Medical Science has already been through phase 1 and has nearly 400 participants lined up for a phase 2 trial. It plans to finish this in November 2021.
Inovio Pharmaceuticals – INO-4800
Inovio Pharmaceuticals has already done some studies on animals and reported successful results and its phase 1 trial on 40 people has good results with an immune response in 94% of patients. It is working with the International Vaccine Institute.
AnGes has partnered with Osaka University and Takara Bio to produce a vaccine. It is currently conducting phases one and two with its product.
Genexine – GX-19
Genexine announced in June that it has approval from South Korea’s Ministry of Food and Drug Safety for a phase one and two trial.
Bharat Biotech – Coro-Flu
Coro-Flu has already been ruled safe for humans under phase one and two trials. It’s now being adapted for coronavirus.
British American Tobacco
One of the most unexpected companies in this list – British American Tobacco – is a tobacco maker. It has a US biotech arm which is using “tobacco plant technology” to create a potential vaccine. The product is awaiting US Food and Drug Administration authorisation to carry out phase one human clinical trials.
Arcturus – LUNAR-COV19
Arcturus’s candidate is currently being tested with the Duke NUS Medical School. It has already signed a deal to supply its vaccine to Israel if it is successful. It’s currently in phase one and two clinical trials.
Compare investment services
More guides on Finder
Coronavirus: Stocks to watch in Lockdown 2
The UK is went back into lockdown on Thursday 5 November. We’ve compiled some lockdown stocks that might see some growth over the next month.
Artificial intelligence stocks
You might think that AI is just something you’ve seen in Black Mirror or Westworld, but it’s slowly working its way into our day to day lives. Find out how you can invest in it.
Best big data stocks to invest in
Big data is a large set of data, and it’s not named big for nothing! Discover how you can invest in companies that source and manage this type of data.
Cloud stocks | Top cloud companies to invest in 2020
Cloud computing stocks have skyrocketed during 2020. In this article we look at the best performers, how to invest in them, and also take a quick look at cloud computing ETFs for you to invest in too.
How to invest in the FTSE 100
The FTSE 100 is the UK’s most famous stock index. Here’s how you can invest in it today.
Brexit currency fallout: Exchange Rate Tracker
Follow the major events of Brexit and how they might affect you with our interactive currency exchange rate tracker.
How to invest in cotton
Ever thought about investing in cotton? Here’s our guide to the investments options at your disposal, the benefits of investing in cotton, as well as the possible risks.
How to invest in gas
Learn how to invest in natural gas, and about gas’s historical performance as an investment. Find out all the need-to-knows with our extensive guide.
Ask an Expert